EE04153B1 - Uudsed guanidiini jäljendid kui faktori Xa inhibiitorid - Google Patents

Uudsed guanidiini jäljendid kui faktori Xa inhibiitorid

Info

Publication number
EE04153B1
EE04153B1 EEP199900583A EEP9900583A EE04153B1 EE 04153 B1 EE04153 B1 EE 04153B1 EE P199900583 A EEP199900583 A EE P199900583A EE P9900583 A EEP9900583 A EE P9900583A EE 04153 B1 EE04153 B1 EE 04153B1
Authority
EE
Estonia
Prior art keywords
imitations
inhibitors
factor
novel guanidine
guanidine
Prior art date
Application number
EEP199900583A
Other languages
English (en)
Estonian (et)
Inventor
Yuk-Sun Lam Patrick
G. Clark Charles
Dominguez Celia
Matthew Fevig John
Han Qi
Li Renhua
Joseph Phillip Pinto Donald
Russell Pruitt James
Lifen Quan Mimi
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE9900583A publication Critical patent/EE9900583A/xx
Publication of EE04153B1 publication Critical patent/EE04153B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP199900583A 1997-06-19 1998-06-18 Uudsed guanidiini jäljendid kui faktori Xa inhibiitorid EE04153B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87888497A 1997-06-19 1997-06-19
PCT/US1998/012680 WO1998057951A1 (fr) 1997-06-19 1998-06-18 NOUVEAUX IMITATEURS DE GUANIDINE UTILISES EN TANT QU'INHIBITEURS DU FACTEUR Xa

Publications (2)

Publication Number Publication Date
EE9900583A EE9900583A (et) 2000-08-15
EE04153B1 true EE04153B1 (et) 2003-10-15

Family

ID=25373029

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900583A EE04153B1 (et) 1997-06-19 1998-06-18 Uudsed guanidiini jäljendid kui faktori Xa inhibiitorid

Country Status (31)

Country Link
EP (1) EP0991638B1 (fr)
JP (1) JP4319255B2 (fr)
KR (1) KR100546522B1 (fr)
CN (1) CN100358888C (fr)
AR (1) AR015391A1 (fr)
AT (1) ATE302198T1 (fr)
AU (1) AU756755B2 (fr)
BR (1) BR9810137A (fr)
CA (1) CA2291442A1 (fr)
DE (1) DE69831238T2 (fr)
DK (1) DK0991638T3 (fr)
EA (1) EA003210B1 (fr)
EE (1) EE04153B1 (fr)
ES (1) ES2244064T3 (fr)
HK (1) HK1028606A1 (fr)
HR (1) HRP980333A2 (fr)
HU (1) HUP0002686A3 (fr)
IL (2) IL133525A0 (fr)
LT (1) LT4705B (fr)
LV (1) LV12496B (fr)
MY (1) MY119820A (fr)
NO (1) NO318359B1 (fr)
NZ (1) NZ502370A (fr)
PL (1) PL192941B1 (fr)
RO (1) RO120543B1 (fr)
SI (1) SI20160B (fr)
SK (1) SK285685B6 (fr)
TW (1) TW544453B (fr)
UA (1) UA57780C2 (fr)
WO (1) WO1998057951A1 (fr)
ZA (1) ZA985247B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
WO1999000121A1 (fr) 1997-06-26 1999-01-07 Eli Lilly And Company Agents antithrombotiques
EP1007037A4 (fr) 1997-06-26 2004-10-06 Lilly Co Eli Agents antithrombotiques
WO1999000128A1 (fr) 1997-06-26 1999-01-07 Eli Lilly And Company Agents antithrombotiques
EP1064270B1 (fr) 1998-03-27 2004-10-06 Bristol-Myers Squibb Pharma Company Pyrazolines et triazolines disubstituees, utilisees en tant qu'inhibiteurs du facteur xa
EP1135023A4 (fr) * 1998-11-12 2003-03-05 Lilly Co Eli Composes aminobenzisoxazole et banques contenant de tels composes
AU3127900A (en) * 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
ATE241621T1 (de) * 1999-04-02 2003-06-15 Bristol Myers Squibb Pharma Co Arylsulfonyle als faktor xa inhibitoren
EP1177188B1 (fr) 1999-05-12 2005-10-12 Ortho-McNeil Pharmaceutical, Inc. Carboxamides de pyrazole utiles pour le traitement de l'obesite et d'autres troubles
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
KR20030011268A (ko) 1999-07-16 2003-02-07 브리스톨-마이어스 스퀴브 파마 컴퍼니 Ｘａ 인자 억제제로서의 질소 함유 헤테로바이사이클
DE19937537A1 (de) * 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6720317B1 (en) * 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
US6407256B1 (en) 1999-11-03 2002-06-18 Bristol Myers Squibb Co Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors
US20020019395A1 (en) * 2000-02-01 2002-02-14 Bing-Yan Zhu Indalone and benzimidazolone inhibitors of factor Xa
CN1439008A (zh) 2000-06-23 2003-08-27 布里斯托尔-迈尔斯斯奎布药品公司 作为因子xa抑制剂的1－(杂芳环基－苯基)－稠合吡唑衍生物
CA2409762A1 (fr) 2000-06-23 2002-01-03 Donald J.P. Pinto Inhibiteurs du facteur xa a substitution heteroaryl-phenyle
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
KR20040043089A (ko) 2000-09-22 2004-05-22 브리스톨-마이어스 스퀴브 파마 컴파니 인자 Ｘａ 억제제의 효과적인 제조 방법
PL204263B1 (pl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003048081A2 (fr) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides en tant qu'inhibiteurs du facteur xa
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
TW200303309A (en) * 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
EP1505966A4 (fr) 2002-05-10 2006-08-30 Bristol Myers Squibb Co Derives cycloalkyles 1,1-disubstitues utilises en tant qu'inhibiteurs du facteur xa
DE10229070A1 (de) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
WO2004031177A1 (fr) * 2002-09-30 2004-04-15 Banyu Pharmaceutical Co., Ltd. Derive de 2-aminobenzimidazole
US20040067995A1 (en) * 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
WO2004048349A1 (fr) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Agonistes de recepteur farnesoide x
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
WO2007002634A1 (fr) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Antagonistes carbocycliques et heherocycliques du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques
ES2360818T3 (es) 2005-06-27 2011-06-09 Bristol-Myers Squibb Company Miméticos de urea lineal antagonistas del receptor p2y, útiles en el tratamiento de afecciones trombóticas.
US7728008B2 (en) 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002635A2 (fr) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Antagonistes cycliques a liaison c du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20100022571A1 (en) 2005-09-16 2010-01-28 Palle Venkata P Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
KR20080087817A (ko) 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 인자 ｘｉａ 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP5342450B2 (ja) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
BRPI0810462A2 (pt) 2007-04-23 2014-10-14 Sanofi Aventis Derivados de quinolina-carboxamida como antagonistas de p2y12
CN101778833A (zh) * 2007-08-10 2010-07-14 日本曹达株式会社 含氮杂环化合物和有害生物防除剂
EP2238128B1 (fr) 2007-12-26 2012-08-22 Sanofi Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
EP3786165A1 (fr) 2010-02-11 2021-03-03 Bristol-Myers Squibb Company Intermédiaires de synthèse utiles à la préparation de macrocycles utilisés en tant qu'inhibiteurs du facteur xia
WO2012098089A1 (fr) 2011-01-19 2012-07-26 Bayer Pharma Aktiengesellschaft Protéines de liaison à des inhibiteurs de facteurs de coagulation
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
CA2851810C (fr) 2011-10-14 2020-01-07 Bristol-Myers Squibb Company Composes de tetrahydroisoquinoleine substitues comme inhibiteurs du facteur xia
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
EA028581B1 (ru) 2012-08-03 2017-12-29 Бристол-Маерс Сквибб Компани ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
EA025392B1 (ru) 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани Дигидропиридон р1 в качестве ингибиторов фактора xia
AU2013348167A1 (en) 2012-11-20 2015-05-28 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
WO2014160668A1 (fr) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tétrahydroisoquinolines comprenant des azoles substitués en tant qu'inhibiteurs du facteur xia
RS57659B1 (sr) 2014-01-31 2018-11-30 Bristol Myers Squibb Co Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia
NO2760821T3 (fr) 2014-01-31 2018-03-10
EP3828173B1 (fr) * 2014-03-07 2022-08-31 BioCryst Pharmaceuticals, Inc. Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
NO2721243T3 (fr) 2014-10-01 2018-10-20
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
WO2017019821A1 (fr) 2015-07-29 2017-02-02 Bristol-Myers Squibb Company Nouveau macrocycle de facteur xia portant un groupe p2' non aromatique
EP3331872B1 (fr) 2015-08-05 2019-09-25 Bristol-Myers Squibb Company Nouveaux inhibiteurs de fxia dérivés de glycine substitués
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
WO2017152117A1 (fr) 2016-03-03 2017-09-08 Cornell University Inhibiteurs ire1-alpha à petites molécules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5317103A (en) 1991-01-15 1994-05-31 Merck Sharp & Dohme Limited Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
AU672802B2 (en) 1992-07-24 1996-10-17 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
WO1995013155A1 (fr) 1993-11-08 1995-05-18 Ishikawajima-Harima Heavy Industries Company Limited Traitement thermique en ligne d'un feuillard d'acier coule en continu
US5612378A (en) * 1995-06-06 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
DE19530996A1 (de) * 1995-08-23 1997-02-27 Boehringer Mannheim Gmbh Cyclische Guanidine, Verfahren zu ihrer Herstellung und Arzneimittel
JP2001502655A (ja) * 1995-12-21 2001-02-27 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害薬であるイソオキサゾリン、イソチアゾリンおよびピラゾリン
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US9607692B2 (en) 2014-10-03 2017-03-28 Micron Technology, Inc. Threshold voltage distribution determination

Also Published As

Publication number Publication date
NO318359B1 (no) 2005-03-07
ES2244064T3 (es) 2005-12-01
SK285685B6 (sk) 2007-06-07
RO120543B1 (ro) 2006-03-30
SK172899A3 (en) 2000-06-12
AU756755B2 (en) 2003-01-23
IL133525A (en) 2006-08-01
ZA985247B (en) 1999-12-17
NZ502370A (en) 2002-10-25
TW544453B (en) 2003-08-01
CA2291442A1 (fr) 1998-12-23
PL337756A1 (en) 2000-09-11
IL133525A0 (en) 2001-04-30
MY119820A (en) 2005-07-29
AR015391A1 (es) 2001-05-02
LV12496B (en) 2001-01-20
PL192941B1 (pl) 2006-12-29
EE9900583A (et) 2000-08-15
HUP0002686A2 (hu) 2002-01-28
LT4705B (lt) 2000-09-25
JP2002505686A (ja) 2002-02-19
CN1259942A (zh) 2000-07-12
CN100358888C (zh) 2008-01-02
SI20160A (sl) 2000-08-31
LT99147A (en) 2000-04-25
NO995965D0 (no) 1999-12-03
EA003210B1 (ru) 2003-02-27
WO1998057951A1 (fr) 1998-12-23
BR9810137A (pt) 2000-08-08
ATE302198T1 (de) 2005-09-15
HK1028606A1 (en) 2001-02-23
EP0991638A1 (fr) 2000-04-12
DE69831238D1 (de) 2005-09-22
EP0991638B1 (fr) 2005-08-17
JP4319255B2 (ja) 2009-08-26
LV12496A (en) 2000-06-20
DK0991638T3 (da) 2005-09-19
SI20160B (sl) 2006-06-30
HRP980333A2 (en) 1999-02-28
EA200000047A1 (ru) 2000-08-28
KR100546522B1 (ko) 2006-01-26
DE69831238T2 (de) 2006-03-23
AU7976898A (en) 1999-01-04
HUP0002686A3 (en) 2002-02-28
NO995965L (no) 1999-12-03
UA57780C2 (uk) 2003-07-15
KR20010014002A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
EE04153B1 (et) Uudsed guanidiini jäljendid kui faktori Xa inhibiitorid
NO20003808D0 (no) Substituerte oksoazaheterosyklylfaktor Xa inhibitorer
ATA900198A (de) Strahlungshärtbares cyanoacrylat-enthaltende zusammensetzung
IS5430A (is) Ný samsetning
BR9801544A (pt) Acumulador
DE69808017D1 (de) D-Prolinderivate
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DE69823822D1 (de) Parallelfluss-filterkopf
DE69817671D1 (de) Antragsrolle
FI970158A (fi) Uusi kuitulevyliima
PT1036083E (pt) Novos 9a-azalidos
DE19756119B4 (de) Heftvorrichtung
IT1303916B1 (it) Difenilammine nonilate
DE69815029D1 (de) Heftvorrichtung
DE69812851D1 (de) Heftvorrichtung
DE69805245D1 (de) Heftvorrichtung
DK0908120T3 (da) Reol
FI972138A0 (fi) Returtraog i bestrykningsanordning
FR2760315B1 (fr) Andaineuse suspendue
FIU970055U0 (fi) Pöytä
SE9701535D0 (sv) Häftapparat
NO975448L (no) L°fteverkt°y
FI971651A0 (fi) Spaormaskin i en elmaskin
FI971698A0 (fi) Klingstyrenhet i en cirkelsaog
FI971123A0 (fi) Foervarings- och transportredskap i synnerhet foer pappersprodukter

Legal Events

Date Code Title Description
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20090618